National STD CurriculumLogo

Lesson 28. Trichomoniasis

PDF Share
Table of Contents
  PDF Share

References

  • Adamski A, Clark RA, Mena L, et al. The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women. Clin Infect Dis. 2014;59:883-7.
  • Aggarwal A, Shier RM. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. J Obstet Gynaecol Can. 2008;30:55-8.
  • Alcaide ML, Feaster DJ, Duan R, et al. The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA. Sex Transm Infect. 2016;92:58-62.
  • Andrea SB, Chapin KC. Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance parameters and epidemiological implications. J Clin Microbiol. 2011;49:866-9.
  • Bachmann LH, Hobbs MM, Seña AC, et al. Trichomonas vaginalis genital infections: progress and challenges. Clin Infect Dis. 2011;53 Suppl 3:S160-72.
  • Badman SG, Causer LM, Guy R, et al. A preliminary evaluation of a new GeneXpert (Gx) molecular point-of-care test for the detection of Trichomonas vaginalis. Sex Transm Infect. 2016;92:350-2.
  • Balkus JE, Richardson BA, Mochache V, et al. A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis. 2013;40:499-505.
  • Bosserman EA, Helms DJ, Mosure DJ, Secor WE, Workowski KA. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure. Sex Transm Dis. 2011;38:983-7.
  • Brown HL, Fuller DD, Jasper LT, Davis TE, Wright JD. Clinical evaluation of affirm VPIII in the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species in vaginitis/vaginosis. Infect Dis Obstet Gynecol. 2004;12:17-21.
  • Brown HL, Fuller DD, Jasper LT, Davis TE, Wright JD. Clinical evaluation of affirm VPIII in the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species in vaginitis/vaginosis. Infect Dis Obstet Gynecol. 2004;12:17-21.
  • Campbell L, Woods V, Lloyd T, Elsayed S, Church DL. Evaluation of the OSOM Trichomonas rapid test versus wet preparation examination for detection of Trichomonas vaginalis vaginitis in specimens from women with a low prevalence of infection. J Clin Microbiol. 2008;46:3467-9.
  • Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg. 2008;78:17-9.
  • Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2015. Other sexually transmitted diseases. Atlanta: U.S. Department of Health and Human Services; 2016.
    [CDC] -
  • Cherpes TL, Wiesenfeld HC, Melan MA, et al. The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis. 2006;33:747-52.
  • Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis. 1997;24:353-60.
  • Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother. 2003;47:1407-9.
  • Davis A, Dasgupta A, Goddard-Eckrich D, El-Bassel N. Trichomonas vaginalis and Human Immunodeficiency Virus Coinfection Among Women Under Community Supervision: A Call for Expanded T. vaginalis Screening. Sex Transm Dis. 2016;43:617-22.
  • Dize L, Barnes P Jr, Barnes M, et al. Performance of self-collected penile-meatal swabs compared to clinician-collected urethral swabs for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium by nucleic acid amplification assays. Diagn Microbiol Infect Dis. 2016;86:131-5.
  • Fastring DR, Amedee A, Gatski M, et al. Co-occurrence of Trichomonas vaginalis and bacterial vaginosis and vaginal shedding of HIV-1 RNA. Sex Transm Dis. 2014;41:173-9.
  • Fouts AC, Kraus SJ. Trichomonas vaginalis: reevaluation of its clinical presentation and laboratory diagnosis. J Infect Dis. 1980;141:137-143.
  • Francis SC, Kent CK, Klausner JD, et al. Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005-2006. Sex Transm Dis. 2008;35:797-800.
  • Freeman AH, Katz KA, Pandori MW, et al. Prevalence and correlates of Trichomonas vaginalis among incarcerated persons assessed using a highly sensitive molecular assay. Sex Transm Dis. 2010;37:165-8.
  • Gatski M, Kissinger P. Observation of probable persistent, undetected Trichomonas vaginalis infection among HIV-positive women. Clin Infect Dis. 2010;51:114-5.
  • Gatski M, Martin DH, Clark RA, Harville E, Schmidt N, Kissinger P. Co-occurrence of Trichomonas vaginalis and bacterial vaginosis among HIV-positive women. Sex Transm Dis. 2011;38:163-6.
  • Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol. 2012;50:2601-8.
  • Helms DJ, Mosure DJ, Metcalf CA, et al. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex Transm Dis. 2008;35:484-8.
  • Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol. 2008;198:370.e1-7.
  • Herbst de Cortina S, Bristow CC, Joseph Davey D, Klausner JD. A Systematic Review of Point of Care Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Infect Dis Obstet Gynecol. 2016;2016:4386127.
  • Hollman D, Coupey SM, Fox AS, Herold BC. Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs. J Pediatr Adolesc Gynecol. 2010;23:312-6.
  • Hoots BE, Peterman TA, Torrone EA, Weinstock H, Meites E, Bolan GA. A Trich-y question: should Trichomonas vaginalis infection be reportable? Sex Transm Dis. 2013;40:113-6.
  • Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. Sex Transm Dis. 2017;44:29-34.
  • Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007;45:194-8.
  • Kelley CF, Rosenberg ES, OʼHara BM, Sanchez T, del Rio C, Sullivan PS. Prevalence of urethral Trichomonas vaginalis in black and white men who have sex with men. Sex Transm Dis. 2012;39:739.
  • Kigozi GG, Brahmbhatt H, Wabwire-Mangen F, et al. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. Am J Obstet Gynecol. 2003;189:1398-400.
  • Kingston MA, Bansal D, Carlin EM. 'Shelf life' of Trichomonas vaginalis. Int J STD AIDS. 2003;14:28-9.
  • Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis. 2012;18:939-43.
  • Kissinger P, Adamski A, Clark RA, Mena L, Levison J, Martin DH. Does antiretroviral therapy interfere with the treatment of Trichomonas vaginalis among HIV+ women? Sex Transm Dis. 2013;40:506-7.
  • Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36:11-6.
  • Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr. 2010;55:565-71.
  • Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307.
  • Kissinger P. Epidemiology and treatment of trichomoniasis. Curr Infect Dis Rep. 2015;17:484.
  • Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med. 2001;345:487-93.
  • Leitsch D. Recent Advances in the Trichomonas vaginalis Field. F1000Res. 2016 Feb 11;5:.
  • Lord E, Newnham T, Dorrell L, et al. Detecting asymptomatic Trichomonas vaginalis in females using the BD ProbeTec™ Trichomonas vaginalis Qx nucleic acid amplification test. Int J STD AIDS. 2016:8:357-61.
  • McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195:698-702.
  • Meites E, Gaydos CA, Hobbs MM, et al. A Review of evidence-based care of symptomatic Trichomoniasis and asymptomatic Trichomonas vaginalis infections. Clin Infect Dis. 2015;61 Suppl 8:S837-48.
  • Meites E, Gaydos CA, Hobbs MM, et al. A review of evidence-based care of symptomatic Trichomoniasis and asymptomatic Trichomonas vaginalis infections. Clin Infect Dis. 2015;61 Suppl 8:S837-48.
  • Meites E, Llata E, Braxton J, et al. Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence. Sex Transm Dis. 2013;40:865-9.
  • Miller M, Liao Y, Gomez AM, Gaydos CA, D'Mellow D. Factors associated with the prevalence and incidence of Trichomonas vaginalis infection among African American women in New York city who use drugs. J Infect Dis. 2008;197:503-9.
  • Mohamed OA, Cohen CR, Kungu D, et al. Urine proves a poor specimen for culture of Trichomonas vaginalis in women. Sex Transm Infect. 2001;77:78-9.
  • Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 2002;34:519-22.
  • Muzny C, Barnes A, Mena L. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health. 2012;9:389-91.
  • Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic. Clin Infect Dis. 2014;59:834-41.
  • Muzny CA, Rivers CA, Mena LA, Schwebke JR. Genotypic characterization of Trichomonas vaginalis isolates among women who have sex with women in sexual partnerships. Sex Transm Dis. 2012;39:556-8.
  • Nijhawan AE, DeLong AK, Celentano DD, et al. The association between Trichomonas infection and incarceration in HIV-seropositive and at-risk HIV-seronegative women. Sex Transm Dis. 2011;38:1094-100.
  • Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200:188.e1-7.
  • Peterman TA, Tian LH, Metcalf CA, Malotte CK, Paul SM, Douglas JM Jr. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis. 2009;48:259-60.
  • Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11:300-17.
  • Roth AM, Williams JA, Ly R, et al. Changing sexually transmitted infection screening protocol will result in improved case finding for Trichomonas vaginalis among high-risk female populations. Sex Transm Dis. 2011;38:398-400.
  • Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187-93.
  • Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50:4209-10.
  • Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol. 2011;49:4106-11.
  • Seña AC, Bachmann LH, Hobbs MM. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther. 2014;12:673-85.
  • Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44:13-22.
  • Stoner KA, Rabe LK, Meyn LA, Hillier SL. Survival of Trichomonas vaginalis in wet preparation and on wet mount. Sex Transm Infect. 2013;89:485-8.
  • Sutcliffe S, Newman SB, Hardick A, Gaydos CA. Prevalence and correlates of Trichomonas vaginalis infection among female US federal prison inmates. Sex Transm Dis. 2010;37:585-90.
  • Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis. 2007;45:1319-26.
  • Swartzendruber A, Sales JM, Brown JL, Diclemente RJ, Rose ES. Correlates of incident Trichomonas vaginalis infections among African American female adolescents. Sex Transm Dis. 2014;41:240-5.
  • Tayal SC, Ochogwu SA, Bunce H. Paromomycin treatment of recalcitrant Trichomonas vaginalis. Int J STD AIDS. 2010;21:217-8.
  • Trintis J, Epie N, Boss R, Riedel S. Neonatal Trichomonas vaginalis infection: a case report and review of literature. Int J STD AIDS. 2010;21:606-7.
  • Van Der Pol B, Kraft CS, Williams JA. Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens. J Clin Microbiol. 2006;44:366-73.
  • Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. 2008;197:548-54.
  • Van Der Pol B, Williams JA, Fuller D, Taylor SN, Hook EW 3rd. Combined Testing for Chlamydia, Gonorrhea, and Trichomonas by Use of the BD Max CT/GC/TV Assay with Genitourinary Specimen Types. J Clin Microbiol. 2017;55:155-64.
  • Van Der Pol B, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis. 2005;192:2039-44.
  • Van Der Pol B. Clinical and Laboratory Testing for Trichomonas vaginalis Infection. J Clin Microbiol. 2016;54:7-12.

Share by e-mail

Check
-On-
Learning
Questions
The Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your understanding of key concepts.

You must be signed in to customize your interaction with these questions.

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.